GMED Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 8.28% compared to Globus Medical's net margin of 11.12%. Globus Medical's return on equity of 2.27% beat Boston Scientific's return on equity of 8.91%.

Globus Medical has a consensus price target of $94.23, signalling upside risk potential of 12.89%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 8.87%. Given that Globus Medical has higher upside potential than Boston Scientific, analysts believe Globus Medical is more attractive than Boston Scientific.

Globus Medical has a beta of 1.190, which suggesting that the stock is 19.035% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical quarterly revenues are $625.7M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Globus Medical's net income of $51.8M is lower than Boston Scientific's net income of $468M. Notably, Globus Medical's price-to-earnings ratio is 124.58x while Boston Scientific's PE ratio is 75.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 4.62x versus 8.49x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 8.28% compared to Globus Medical's net margin of 9.79%. Globus Medical's return on equity of 2.27% beat Haemonetics's return on equity of 13.51%.

Globus Medical has a consensus price target of $94.23, signalling upside risk potential of 12.89%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 43.13%. Given that Haemonetics has higher upside potential than Globus Medical, analysts believe Haemonetics is more attractive than Globus Medical.

Globus Medical has a beta of 1.190, which suggesting that the stock is 19.035% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $625.7M, which are larger than Haemonetics quarterly revenues of $345.5M. Globus Medical's net income of $51.8M is higher than Haemonetics's net income of $33.8M. Notably, Globus Medical's price-to-earnings ratio is 124.58x while Haemonetics's PE ratio is 32.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 4.62x versus 2.92x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 8.28% compared to Globus Medical's net margin of 14.25%. Globus Medical's return on equity of 2.27% beat Insulet's return on equity of 49.55%.

Globus Medical has a consensus price target of $94.23, signalling upside risk potential of 12.89%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 8.51%. Given that Globus Medical has higher upside potential than Insulet, analysts believe Globus Medical is more attractive than Insulet.

Globus Medical has a beta of 1.190, which suggesting that the stock is 19.035% more volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Globus Medical quarterly revenues are $625.7M, which are larger than Insulet quarterly revenues of $543.9M. Globus Medical's net income of $51.8M is lower than Insulet's net income of $77.5M. Notably, Globus Medical's price-to-earnings ratio is 124.58x while Insulet's PE ratio is 45.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 4.62x versus 10.14x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 8.28% compared to Globus Medical's net margin of 25.43%. Globus Medical's return on equity of 2.27% beat ResMed's return on equity of 23.76%.

Globus Medical has a consensus price target of $94.23, signalling upside risk potential of 12.89%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 8.83%. Given that Globus Medical has higher upside potential than ResMed, analysts believe Globus Medical is more attractive than ResMed.

Globus Medical has a beta of 1.190, which suggesting that the stock is 19.035% more volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Globus Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Globus Medical pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical quarterly revenues are $625.7M, which are smaller than ResMed quarterly revenues of $1.2B. Globus Medical's net income of $51.8M is lower than ResMed's net income of $311.4M. Notably, Globus Medical's price-to-earnings ratio is 124.58x while ResMed's PE ratio is 30.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical is 4.62x versus 7.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.